Should I buy or sell Aravive stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares. View ARAV analyst ratings or view top-rated stocks .

What is Aravive's stock price target for 2024?

4 analysts have issued twelve-month price objectives for Aravive's shares. Their ARAV share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $13.50 in the next year. This suggests a possible upside of 33,565.8% from the stock's current price. View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts .

How have ARAV shares performed in 2024?

Aravive's stock was trading at $0.1237 at the beginning of the year. Since then, ARAV stock has decreased by 67.6% and is now trading at $0.0401. View the best growth stocks for 2024 here .

When is Aravive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ARAV earnings forecast .

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) released its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Applied Genetic Technologies (AGTC) , Flexion Therapeutics (FLXN) , Inovio Pharmaceuticals (INO) , T2 Biosystems (TTOO) , Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX) .

How do I buy shares of Aravive?

Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARAV

Aravive (ARAV) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free ARAV Stock Alerts

$0.04

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.04
▼
$0.04
50-Day Range: $0.04
▼
$0.04
52-Week Range: $0.04
▼
$2.46

Volume: N/A
Average Volume: N/A
Market Capitalization: $2.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Get Aravive alerts:

Aravive MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 33,565.8% Upside
$13.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Aravive has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aravive has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ARAV.

0.0

Dividend Strength

Dividend Yield
Aravive does not currently pay a dividend.
Dividend Growth
Aravive does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Aravive has received a 71.21% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Aravive is -0.77.

0.0

News and Social Media Coverage

Search Interest
Only 6 people have searched for ARAV on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aravive insiders have not sold or bought any company stock.
Percentage Held by Insiders
60.40% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 35.80% of the stock of Aravive is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aravive has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Aravive Stock (NASDAQ:ARAV)

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

ARAV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARAV Stock News Headlines

April 2, 2024 | finance.yahoo.com

Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsight

January 30, 2024 | finance.yahoo.com

Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

January 18, 2024 | msn.com

Crude Oil Rises Over 1%; Processa Pharmaceuticals Shares Slide

January 18, 2024 | msn.com

Why Is Nuvve (NVVE) Stock Down 31% Today?

January 18, 2024 | markets.businessinsider.com

Why Is Aravive (ARAV) Stock Down 52% Today?

January 17, 2024 | marketwatch.com

Aravive Shares Drop 53%, Company to Delist and Deregister Stock

January 17, 2024 | finance.yahoo.com

Aravive, Inc. to Delist from The Nasdaq Stock Market

April 16, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

December 27, 2023 | benzinga.com

Aravive Stock (NASDAQ:ARAV), Short Interest Report

December 27, 2023 | benzinga.com

Aravive Stock (NASDAQ:ARAV) Dividends: History, Yield and Dates

December 8, 2023 | bizjournals.com

Houston is building it. Why won't they come?

November 20, 2023 | bizjournals.com

Houston companies, universities win nearly $50.7 million in latest CPRIT awards

November 12, 2023 | morningstar.com

Aravive Inc ARAV

October 13, 2023 | finance.yahoo.com

Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?

September 24, 2023 | finance.yahoo.com

Aravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo Finance

August 29, 2023 | benzinga.com

Thinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?

August 23, 2023 | 247wallst.com

Cantor Fitzgerald Downgrades Aravive

August 22, 2023 | msn.com

Cantor Fitzgerald Downgrades Aravive (ARAV)

August 22, 2023 | msn.com

Cantor cuts Aravive to neutral as biotech struggles to stay in business

August 22, 2023 | markets.businessinsider.com

Analyst Downgrades Aravive: Grapples With Trial Setback, Strategic Alternatives

August 4, 2023 | msn.com

William Blair Downgrades Aravive (ARAV)

August 3, 2023 | msn.com

Aravive (ARAV) Price Target Decreased by 5.77% to 12.50

August 3, 2023 | seekingalpha.com

Aravive sinks as Phase 3 ovarian cancer trial for lead asset fails

August 3, 2023 | msn.com

Aravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian Cancer

August 3, 2023 | marketwatch.com

Aravive Shares Hit 52-Week Low After Trial Misses Primary Endpoint

August 3, 2023 | markets.businessinsider.com

H.C. Wainwright downgrades Aravive (ARAV) to a Hold

See More Headlines

Receive ARAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/27/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARAV
CUSIP: N/A
CIK: 1513818
Web: www.aravive.com
Phone: (936) 355-1910
Fax: N/A
Employees: 23
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.50
High Stock Price Target: $18.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +33,565.8%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,320,000.00
Net Margins: -569.65%
Pretax Margin: -569.65%
Return on Equity: N/A
Return on Assets: -99.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.98
Quick Ratio: 0.98

Sales & Book Value

Annual Sales: $9.14 million
Price / Sales: 0.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.18 per share
Price / Book: 0.22

Miscellaneous

Outstanding Shares: 73,560,000
Free Float: 29,131,000
Market Cap: $2.95 million
Optionable: Optionable
Beta: 2.10

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Fredric N. Eshelman Pharm.D. (Age 75)
Executive Chairman
Comp: $95k
Dr. Jeffrey L. Cleland Ph.D. (Age 59)
Co-Founder
Comp: $669.98k
Dr. Joshua Aaron Silverman Ph.D.
Co-Founder
Mr. Marek Ciszewski J.D.
Vice President of Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ARAV Stock Analysis - Frequently Asked Questions

Should I buy or sell Aravive stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares.
View ARAV analyst ratings or view top-rated stocks.
What is Aravive's stock price target for 2024?: 4 analysts have issued twelve-month price objectives for Aravive's shares. Their ARAV share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $13.50 in the next year. This suggests a possible upside of 33,565.8% from the stock's current price.
View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts.
How have ARAV shares performed in 2024?: Aravive's stock was trading at $0.1237 at the beginning of the year. Since then, ARAV stock has decreased by 67.6% and is now trading at $0.0401.
View the best growth stocks for 2024 here.
When is Aravive's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ARAV earnings forecast.

How were Aravive's earnings last quarter?: Aravive, Inc. (NASDAQ:ARAV) released its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company earned $2.41 million during the quarter, compared to analyst estimates of $2.36 million.
What other stocks do shareholders of Aravive own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).
How do I buy shares of Aravive?: Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARAV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aravive (ARAV) Stock Price, News & Analysis

Aravive MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Aravive Stock (NASDAQ:ARAV)

ARAV Stock Price History

ARAV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ARAV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™